A Multi-Site Clinical Evaluation of the ARIES Group A Strep Assay in Symptomatic Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
-
Florida
-
Pensacola, Florida, United States, 32504
- Sacred Heart Hospital
-
-
Missouri
-
Kansas City, Missouri, United States, 54449
- Children's Mercy Hospital
-
-
Virginia
-
Vienna, Virginia, United States, 22180
- Advanced Pediatrics Research
-
-
Wisconsin
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Labs
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient and/or patient's legal guardian is willing and able to give informed consent and/or assent for extra research sample.
- The subject's specimen is a throat swab in Liquid Amies based transport medium.
- The specimen is from an adult or pediatric, male or female subject who is either hospitalized, admitted to a hospital emergency department, visiting an outpatient clinical or resident of a long term care facility.
- The specimen is from a patient for whom a requisition has been made for Group A Strep testing
- The specimen is from a patient exhibiting clinical signs and symptoms of pharyngitis consistent with Group A Strep infection.
- The specimen was received in good condition (no leakage or drying of the specimen).
- The specimen volume is ≥ 850 µL.
Exclusion Criteria:
- The specimen is from a patient who did not provide informed consent/assent.
- The specimen is not a throat swab collected in Liquid Amies based transport medium.
- The specimen is from a patient who is undergoing antibiotic treatment.
- The specimen was not properly collected, transported, processed or stored according to the instructions provided by the Sponsor in Section 9 below.
- The specimen volume is < 850 µL.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group A Strep Assay
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical performance (sensitivity/specificity) for Group A Strep Assay
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Ronald Dunn, Luminex Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LMA-GAS-01-CS-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.